These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 38018328)
21. Intensive Models of Hepatitis C Care for People Who Inject Drugs Receiving Opioid Agonist Therapy: A Randomized Controlled Trial. Akiyama MJ; Norton BL; Arnsten JH; Agyemang L; Heo M; Litwin AH Ann Intern Med; 2019 May; 170(9):594-603. PubMed ID: 30959528 [TBL] [Abstract][Full Text] [Related]
22. Hepatitis C virus elimination in Swiss opioid agonist therapy programmes - the SAMMSU cohort. Bregenzer A; Bruggmann P; Castro E; Moriggia A; Rothen M; Thurnheer MC; Vernazza P; Scheidegger C Swiss Med Wkly; 2021 Mar; 151():w20460. PubMed ID: 33705563 [TBL] [Abstract][Full Text] [Related]
23. Hepatitis C reinfection by treatment pathway among people who inject drugs in Tayside, Scotland. Caven M; Baiano CX; Robinson EM; Stephens B; Macpherson I; Dillon JF J Viral Hepat; 2021 Dec; 28(12):1744-1750. PubMed ID: 34525228 [TBL] [Abstract][Full Text] [Related]
24. 'Treat my whole person, not just my condition': qualitative explorations of hepatitis C care delivery preferences among people who inject drugs. Tsui JI; Barry MP; Austin EJ; Sweek EW; Tung E; Hansen RN; Ninburg M; Scott JD; Glick SN; Williams EC Addict Sci Clin Pract; 2021 Aug; 16(1):52. PubMed ID: 34384494 [TBL] [Abstract][Full Text] [Related]
25. Hepatitis C treatment uptake among people who inject drugs in Oslo, Norway: A registry-based study. Malme KB; Ulstein K; Finbråten AK; Wüsthoff LEC; Kielland KB; Hauge J; Dalgard O; Midgard H Int J Drug Policy; 2023 Jun; 116():104044. PubMed ID: 37149914 [TBL] [Abstract][Full Text] [Related]
26. Changes in incidence of hepatitis C virus reinfection and access to direct-acting antiviral therapies in people with HIV from six countries, 2010-19: an analysis of data from a consortium of prospective cohort studies. Sacks-Davis R; van Santen DK; Boyd A; Young J; Stewart A; Doyle JS; Rauch A; Mugglin C; Klein M; van der Valk M; Smit C; Jarrin I; Berenguer J; Lacombe K; Requena MB; Wittkop L; Leleux O; Bonnet F; Salmon D; Matthews GV; Guy R; Martin NK; Spelman T; Prins M; Stoove M; Hellard M; Lancet HIV; 2024 Feb; 11(2):e106-e116. PubMed ID: 38224708 [TBL] [Abstract][Full Text] [Related]
27. Low hepatitis C virus reinfection rate despite ongoing risk following universal access to direct-acting antiviral therapy among people living with HIV. Hosseini-Hooshyar S; Martinello M; Yee J; Read P; Baker D; Post JJ; Finlayson R; Bloch M; Doyle JS; Shaw D; Hellard M; Petoumenos K; Carson J; Dore GJ; Matthews GV; AIDS; 2020 Jul; 34(9):1347-1358. PubMed ID: 32590433 [TBL] [Abstract][Full Text] [Related]
28. Treatment adherence and support for people who inject drugs taking direct-acting antiviral therapy for hepatitis C infection. Read P; Gilliver R; Kearley J; Lothian R; Cunningham EB; Chronister KJ; Dore GJ J Viral Hepat; 2019 Nov; 26(11):1301-1310. PubMed ID: 31299127 [TBL] [Abstract][Full Text] [Related]
29. Treatment for hepatitis C virus infection among people who inject drugs attending opioid substitution treatment and community health clinics: the ETHOS Study. Grebely J; Alavi M; Micallef M; Dunlop AJ; Balcomb AC; Phung N; Weltman MD; Day CA; Treloar C; Bath N; Haber PS; Dore GJ; Addiction; 2016 Feb; 111(2):311-9. PubMed ID: 26451534 [TBL] [Abstract][Full Text] [Related]
30. Determining the frequency and characteristics of Hepatitis C reinfections in North East England. Askar S; Jelley R; McQue K; Allsop C; McCullough F; Miller C; Taha Y; Masson S; McPherson S J Viral Hepat; 2022 Aug; 29(8):685-690. PubMed ID: 35643915 [TBL] [Abstract][Full Text] [Related]
31. Assessment of factors affecting response of direct-acting antivirals in chronic hepatitis C patients. Jain N; Garg R; Singh GP; Kaur S; Chawla SPS; Padda P Ann Afr Med; 2023; 22(4):456-464. PubMed ID: 38358146 [TBL] [Abstract][Full Text] [Related]
32. High rates of early HCV reinfection after DAA treatment in people with recent drug use attended at mobile harm reduction units. Valencia J; Alvaro-Meca A; Troya J; Cuevas G; Gutiérrez J; Morro A; Alvarez J; Pulido L; Cañamares I; Escobar I; Moreno S; Ryan P Int J Drug Policy; 2019 Oct; 72():181-188. PubMed ID: 31253391 [TBL] [Abstract][Full Text] [Related]
33. Direct acting antiviral-based treatment of hepatitis C virus infection among people who inject drugs in Georgia: A prospective cohort study. Bouscaillou J; Kikvidze T; Butsashvili M; Labartkava K; Inaridze I; Etienne A; Le Pluart D; Kamkamidze G; Gamezardashvili A; Kharshiladze D; Avril E; Luhmann N Int J Drug Policy; 2018 Dec; 62():104-111. PubMed ID: 30384026 [TBL] [Abstract][Full Text] [Related]
34. HCV elimination in a Swiss opioid agonist therapy programme - a cohort study. Bregenzer A; Krismer C; Wendel S; Roser P; Fux CA Swiss Med Wkly; 2022 Dec; 152():40009. PubMed ID: 36509421 [TBL] [Abstract][Full Text] [Related]
35. Randomized clinical trial: Direct-acting antivirals as treatment for hepatitis C in people who inject drugs: Delivered in needle and syringe programs via directly observed therapy versus fortnightly collection. Beer L; Inglis S; Malaguti A; Byrne C; Sharkey C; Robinson E; Gillings K; Radley A; Hapca A; Stephens B; Dillon J J Viral Hepat; 2022 Aug; 29(8):646-653. PubMed ID: 35582875 [TBL] [Abstract][Full Text] [Related]
36. Progress Towards Elimination of Hepatitis C Infection Among People Who Inject Drugs in Australia: The ETHOS Engage Study. Valerio H; Alavi M; Silk D; Treloar C; Martinello M; Milat A; Dunlop A; Holden J; Henderson C; Amin J; Read P; Marks P; Degenhardt L; Hayllar J; Reid D; Gorton C; Lam T; Dore GJ; Grebely J Clin Infect Dis; 2021 Jul; 73(1):e69-e78. PubMed ID: 32421194 [TBL] [Abstract][Full Text] [Related]
37. An intervention to increase hepatitis C virus diagnosis and treatment uptake among people in custody in Iran. Hariri S; Alavi M; Roshandel G; Mohammadi Z; Fazel A; Amiriani T; Bazazan A; Motamed-Gorji N; Sohrabpour A; Merat S; Poustchi H; Malekzadeh R Int J Drug Policy; 2021 Sep; 95():103269. PubMed ID: 33991887 [TBL] [Abstract][Full Text] [Related]
38. Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study. Grebely J; Dalgard O; Cunningham EB; Hajarizadeh B; Foster GR; Bruggmann P; Conway B; Backmund M; Robaeys G; Swan T; Amin J; Marks PS; Quiene S; Applegate TL; Weltman M; Shaw D; Dunlop A; Hellard M; Bruneau J; Midgard H; Bourgeois S; Staehelin C; Dore GJ; Int J Drug Policy; 2017 Sep; 47():177-186. PubMed ID: 28624134 [TBL] [Abstract][Full Text] [Related]
39. On-site testing and case management to improve hepatitis C care in drug users: a prospective, longitudinal, multicenter study in the DAA era. Busschots D; Bielen R; Koc ÖM; Heyens L; Dercon E; Verrando R; Janssens F; Van den Bergh L; Van Lint P; Bruckers L; Nevens F; Robaeys G BMC Public Health; 2021 Aug; 21(1):1574. PubMed ID: 34416867 [TBL] [Abstract][Full Text] [Related]
40. Impact of direct-acting antivirals for HCV on mortality in a large population-based cohort study. Janjua NZ; Wong S; Abdia Y; Jeong D; Buller-Taylor T; Adu PA; Samji H; Wilton J; Pearce M; Butt ZA; Yu A; Binka M; Bartlett S; Alvarez M; Krajden M J Hepatol; 2021 Nov; 75(5):1049-1057. PubMed ID: 34097994 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]